IRON

Business Context and Reporting Period

Company: Disc Medicine, Inc. (Nasdaq: IRON)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2024
Business Overview: Disc Medicine is a clinical-stage biopharmaceutical company focused on developing novel treatments for serious hematologic diseases. The company targets fundamental biological pathways associated with red blood cell formation, specifically heme biosynthesis and iron homeostasis. It has no products approved for commercial sale and has not generated any revenue from product sales.

Key Financial Metrics

Note: The company reported interest income of $21.3 million in 2024, partially offsetting operating losses.

Material Changes vs. Prior Period

• Increased Operating Loss: Net loss increased by $33.0 million (43%) year-over-year, driven primarily by higher R&D and SG&A expenses.
• R&D Expense Growth: R&D expenses rose by $27.4 million, attributed to increased personnel costs (including $5.3 million in stock-based compensation) and external development costs for advancing clinical trials of bitopertin and DISC-0974. This was partially offset by a decrease in DISC-3405 expenses due to the absence of the $15.0 million upfront license fee paid to Mabwell in 2023.
• SG&A Expense Growth: SG&A expenses increased by $11.2 million, primarily due to higher personnel-related costs and stock-based compensation.
• Debt Financing: In November 2024, the company entered into a Loan and Security Agreement with Hercules Capital, Inc., borrowing an initial $30.0 million. This represents a new material liability not present in the prior year.
• Investment Activity: Significant cash outflow from investing activities ($292.3 million) in 2024 due to the purchase of marketable securities, compared to minimal investing activity in 2023.

Guidance, Outlook, and Risks

Management Commentary and Outlook

• Liquidity: As of December 31, 2024, the company held $489.9 million in cash and marketable securities. Following a January 2025 underwritten offering yielding approximately $243.3 million in net proceeds, management believes funds are sufficient to operate into 2028.
• Bitopertin (Lead Asset): The FDA agreed that reduction of protoporphyrin IX (PPIX) may serve as a surrogate endpoint for accelerated approval in Erythropoietic Protoporphyria (EPP) and X-linked Protoporphyria (XLP). The company plans to initiate the APOLLO post-marketing confirmatory trial by mid-2025 and anticipates submitting a New Drug Application (NDA) in the second half of 2025.
• DISC-0974: Phase 2 open-label trial in anemia of myelofibrosis was initiated in December 2024. Initial data is expected in the second half of 2025.
• DISC-3405: Phase 1 data in healthy volunteers was presented in December 2024. A Phase 2 trial in Polycythemia Vera (PV) is planned for initiation in the first half of 2025.

Risks and Contingencies

• Internal Control Material Weakness: The company identified a material weakness in internal control over financial reporting related to ineffective Information Technology General Controls (ITGCs) over key financial IT systems. This resulted in an adverse opinion from the independent auditor on internal controls, though the financial statements received an unqualified opinion.
• Capital Requirements: The company has incurred significant losses since inception and expects to continue doing so. Future funding may be required, and failure to raise capital could force delays in development programs.
• Regulatory and Clinical Risks: Success depends on the outcome of clinical trials and regulatory approvals. The company relies on third-party CDMOs for manufacturing, creating supply chain risks.
• Debt Covenants: The Hercules Loan Agreement includes covenants, including a minimum cash covenant, which could restrict operational flexibility if not met.

Key Facts for Investor Verification

• Internal Control Remediation: Verify the progress of remediation efforts for the identified material weakness in ITGCs and whether additional weaknesses are discovered.
• Bitopertin NDA Timeline: Monitor the initiation of the APOLLO trial and the submission of the NDA for accelerated approval in H2 2025 as planned.
• Cash Burn Rate: Track quarterly cash burn against the projected runway into 2028, considering the impact of the new debt service obligations.
• Clinical Trial Data: Review upcoming data releases for DISC-0974 (H2 2025) and DISC-3405 (H2 2025) to assess efficacy and safety profiles.
• License Milestones: Note the $3.0 million milestone payment made to AbbVie in January 2025 and monitor future contingent payments under license agreements with Roche, AbbVie, and Mabwell.